Catherine H. Marshall, MD, MPH

Melissa Reimers, MD

Tanya Dorff, MD

GU Oncology Now

Drs. Catherine Marshall, Melissa Reimers, and Tanya Dorff continue their discussion on toxicities from single-agent and combination-based HR inhibitors. The trio also predicts whether patients without HRR mutations will be able to receive PARP inhibitors in the future.What are the essentials to know about toxicity from single agent and combination therapy HR inhibitors? Which patients should and should not receive combination therapy? Will there ever come a point when patients without HRR mutations should receive PARP inhibitors?View their previous comments on <a href="https://guoncologynow.com/post/acting-on-actionable-mutations-genetic-testing-and-parp-inhibitors-for-advanced-prostate-cancer" target="_blank" rel="noopener">Genetic Testing and PARP Inhibitors for Advanced Prostate Cancer</a>.

Acting on Actionable Mutations: Toxicities From Single-Agent, Combination PARP Inhibitors for Advanced Prostate Cancer

Metastatic castration-resistant prostate cancer 

CRPC

Drs. Marshall, Reimers, and Dorff continue their discussion on toxicities from single-agent and combination-based HR inhibitors.

Toxicities From Single-Agent, Combination PARPi for aPC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe